No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - The chief executive officer of Tissue Regenix, Steve Couldwell, will be taking a leave of absence from the start of the next year as he undergoes medical treatment.
During his absence, which is expected to span the first quarter, the board has approved interim management changes to ensure the continuity of the group's strategy. Chairman John Samuel will become executive chairman and Gareth Jones, the current chief financial officer, will become chief operating officer.
John Samuel said: "Steve has done an excellent job of establishing a sound business strategy and delivering positive sales momentum. We are confident we will continue to execute against this strategy and on behalf of the board and everyone at Tissue Regenix, I wish Steve a full and speedy recovery."
The AIM-listed medical technology company also gave a one-line update on trading, saying current trading for FY18 remains in line with the board's expectations.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.